In the CLL mouse model, dual anti-PD-1/LAG-3 therapy reduced the percentage and number of CLL cells in both the blood and spleen, thus effectively reducing the tumor burden in CLL-infected animals, which represented an effective treatment for restoring a functional antitumor immune response. This evidence concerns the gene LAG3 and B-cell chronic lymphocytic leukemia.